Challenges in vascular dementia research

Disease Management and Health Outcomes

Volumn 2, Issue SUPPL. 1, 1997, Pages 37-44

  Moller H J ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008353913     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199700021-00007     Document Type: Article

References (33)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association, 1994
2. Wetterling T, Kanitz RD, Borgis KJ. The ICD-10 criteria for vascular dementia. Dementia 1994; 5: 185-8
3. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-60
4. Chui HC, Victoroff JI, Margolin D, et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's disease diagnostic and treatment centers. Neurology 1992; 42: 473-80
5. Galasko D, Hansen L, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994; 51: 888-95
6. Rockwood K, Stadnyk K. The prevalence of dementia in the elderly: a review. Can J Psychiatry 1994; 39: 253-7
7. Hebert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 1995; 14: 240-57
8. The Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994; 150: 899-913
9. Sulkava R, Wikström J, Aromaa A, et al. Prevalence of severe dementia in Finland. Neurology 1985; 35: 1025-9
10. Ueda K, Kawano H, Hasuo Y, et al. Prevalence and etiology of dementia in a Japanese community. Stroke 1992; 23: 798-803
11. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-7
12. Swanwick G, Coen RF, Lawlor BA, et al. Discriminating power of the Hachinski ischaemic score in a geriatric population with mild dementia. Int J Geriat Psych 1995; 10: 679-85
13. Empfehlungen zum Wirksamkeitsnachweis von Nootropika im Indikationsbereich Demenz (Phase III). Recommendations for the proof of efficacy of nootropics in dementia (Phase III). Bundesgesundheitsblatt 1991; 7: 343-50
14. CPMP note for guidance on anti dementia medicinal products (EWP/553/95) draft 11. The European Agency for the Evaluation of Medicinal Products: London, 1996
15. National Institute of Mental Health: 028 CGI. Clinical Global Impression. In: Guy W, editor. ECDEU Assessment for psychopharmacology. Rev ed. Rockville, Maryland: 1976, 217-22
16. Knopman DS, Knapp MJ, Gracon SI, et al. The clinician interview-based impression (CIBI): a clinician's global change rating in Alzheimer's disease. Neurology 1994; 44: 2315-21
17. Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment of geriatric populations: Sandoz Clinical Assessment - Geriatric (SCAG). J Am Geriat Soc 1974; 22: 107-13
18. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64
19. Black RS, Barclay L, Nolan K, et al. Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc 1992; 40: 237-44
20. Spiegel R, Brunner C, Ermini-Funfschilling D, et al. A new behavioral assessment scale for geriatric out- and inpatients: the NOSGER (Nurses' observation scale for geriatric patients). J Am Geriatr Soc 1991; 39: 339-47
21. Maloteaux JM, Haiech J, De Campaneere D, et al. Biochemical and physiological evidences for antiserotonergic properties of naftidrofuryl. Arzneimittel Forschung 1986; 36/8: 1194-8
22. Oudart N. Naftidrofuryl inhibits contractions to serotonin in intact and de-endothelialized cerebral arteries in vitro. J Cardiovasc Pharmacol 1990; 16: Suppl. 3: S45-8
23. Kirsten R, Erdeg B, Moxler D, et al. Platelet aggregation after naftidrofuryl application in vitro and ex vivo. Clin Pharm Ther 1995; 33: 81-4
24. Kiesewetter H, Jung F. Wirkung von Naftidrofuryl auf Makro-, Mikrozirkulation, Gewebssauerstoffversorgung und Fliessfahigkeit des Blutes. (Effects of naftidrofuryl on macro-microcirculation, tissue oxygenation and blood viscosity.) VASA 1988; 17: Suppl. 24: 21-6
25. Soler C, Caillot A, Amoussou Guenou K, et al. Quantitative rheological evaluation of the effect of naftidrofuryl on disorders of the cerebral microcirculation. Clin Hemorheol 1995; 15: 167-76
26. Takeo S, Miyake K, Minematsu R, et al. In vitro effect of naftidrofuryl oxalate on cerebral mitochondria impaired by microsphere-induced embolism in rats. J Pharm Exp Ther 1989; 248: 1207-14
27. Dagani F, Marzatico F, Curti D, et al. Effect of prolonged and intermittent hypoxia on some cerebral enzymatic activities related to energy transduction. J Cereb Blood Flow Metab 1984; 4: 615-24
28. Yesavage JA, Tinklenberg JR, Hollister LE, et al. Effect of naftidrofuryl on lactate and pyruvate in the cerebrospinal fluid of patients with senile dementia. J Am Geriatr Soc 1982; 30: 105-8
29. Lamproglou Y, Le Poncin M, Jacques W, et al. Postischemic breakdown in hippocampal protein synthesis and amnesic deficits in rats: pharmacological improvement by curative naftidrofuryl treatment. Metabol Brain Dis 1992; 7: 165-74
30. Bornstein S, Tastayre R, Mosnier M, et al. Etude double-aveugle de l'efficacité du naftidrofuryl dans les troubles cognitifs liés à la senescence. (Double-blind study of the efficacy of naftidrofuryl in the cognition deficiency due to senescence.) Rev Gériatrie 1993; 18: 355-62
31. Grossman WM, Standl A, May U, et al. Naftidrofuryl in the treatment of mild senile dementia. A double blind study. Pharmacopsychiatry 1990; 23: 265-73
32. Israel L, Dell Accio E, Hugonot R. Action combinée du praxilène et d'exercises d'entrainement mental sur les troubles de la mémoire de sûjets agés. Praxilene and memory training programs. A double blind study of combined therapy in elderly patients with memory impairments. Psychol Med 1989; 21: 1219-34
33. Saldmann F, Funel A, Jacquet P. Efficacy of naftidrofuryl in patients with moderate senile dementia. Curr Med Res Opin 1991; 12: 379-89